Health

  • January 12, 2026

    15,000 Nurses Begin Strike On Major NYC Hospitals

    Thousands of nurses at three New York City hospital systems walked off the job Monday, heralding what their union called the largest nurses' strike in the city's history after the systems refused to meet workers' demands on staffing, benefits and work safety protocol during contract negotiations.

  • January 12, 2026

    DC Circ. Told $100K H-1B Fee Threatens Congress' Tax Power

    The U.S. Chamber of Commerce urged the D.C. Circuit to bar the Trump administration from charging employers its new $100,000 H-1B visa fee, arguing it presents a "grave threat" to Congress' exclusive power to levy taxes.

  • January 12, 2026

    HHS' Pediatric Health Cuts Blocked As Likely 'Retaliatory'

    A D.C. federal judge has temporarily blocked the U.S. Department of Health and Human Services from cutting nearly $12 million in pediatric health funding to the American Academy of Pediatrics, finding HHS could be retaliating for a lawsuit challenging the agency's changes to members on a federal vaccine committee. 

  • January 12, 2026

    Medicine Biz Mirador Wraps $250M Funding Round

    San Diego-based clinical-stage precision medicine company Mirador Therapeutics Inc. announced Monday that it closed its Series B funding round with $250 million of investor commitments, bringing the company's total capital raised since its March 2024 launch to more than $650 million.

  • January 12, 2026

    Justices Nix Petition On Legal Malpractice Arbitration

    The U.S. Supreme Court declined Monday to review a petition that sought clarity on whether a court or arbitrator decides the issue of class arbitrability when the parties incorporate certain arbitral rules, in a long, winding legal malpractice dispute involving Louisiana medical companies.

  • January 12, 2026

    Justices Want SG Input On Arthritis Drug Competition Fight

    The U.S. Supreme Court on Monday asked the Trump administration to weigh in on whether state unfair competition claims should be used to block a competitor from selling compounded versions of drugs in certain states.

  • January 12, 2026

    High Court Won't Take On No Surprises Act Enforcement Row

    The U.S. Supreme Court on Monday declined to weigh in on whether the No Surprises Act denies providers a private right to enforce dispute resolution awards against insurers over emergency care coverage.

  • January 12, 2026

    No High Court Review For California Opioid 'Nuisance' Suit

    The U.S. Supreme Court on Monday said it would not weigh in on a circuit court decision that a California public nuisance lawsuit against pharmacy benefit managers over their opioid-dispensing practices belongs in state court.

  • January 12, 2026

    Justices Pass On Houston Hospital Workers' COVID Vax Fight

    The U.S. Supreme Court declined Monday to hear a challenge to a Houston hospital's win in a lawsuit brought by a group of employees who said they were unlawfully terminated after refusing the COVID-19 vaccine.

  • January 12, 2026

    Justices Won't Weigh Collective Cert. Process In Eli Lilly Case

    The U.S. Supreme Court declined on Monday to review whether courts should stick with a long-standing two-step analysis for certifying collective actions in an age discrimination case against Eli Lilly and Co. that could have affected wage and hour litigation.

  • January 09, 2026

    Mangione Says Defective Charges Doom Federal Murder Rap

    Counsel for Luigi Mangione on Friday urged a Manhattan federal judge to throw out the most serious charges brought against the alleged killer of UnitedHealthcare CEO Brian Thompson, saying prosecutors have failed to allege crimes of violence as predicate offenses to support murder and weapons charges.

  • January 09, 2026

    Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims

    A Connecticut federal judge on Friday refused to hand a quick win to Mylan Pharmaceuticals and Aurobindo Pharma USA in sprawling antitrust litigation against 26 total pharmaceutical companies, ruling that a coalition of states has enough evidence to raise a genuine dispute about whether the companies conspired to fix drug prices.

  • January 09, 2026

    Up Next At High Court: Pollution Lawsuits & Trans Athletes

    The U.S. Supreme Court will kick off the new year by hearing disputes over the constitutionality of state laws banning transgender female athletes from female-only sports and whether state or federal courts are the proper forum for lawsuits seeking to hold major oil companies accountable for harm caused by their oil production activities along Louisiana's coast. 

  • January 09, 2026

    $500K Revelation Doesn't Nix Surgeon's Win In Eye Injury Row

    A California appeals court won't order a retrial in a suit alleging a surgery center blinded a patient in one eye during spinal surgery, saying she failed to properly object to a closing argument that implied that a co-defendant's settlement was the source of $500,000 she had received.

  • January 09, 2026

    Wash. Gov. Pitches Bills On AI Chatbots, Vaccines, Housing

    Washington state's governor announced six bills Friday that he's asking lawmakers to pass in the legislative session that kicks off Monday, including measures to increase housing, guard Washingtonians from people posing as law enforcement, reinforce the state's vaccine decision-making authority and establish protections around AI chatbots, particularly for youth.

  • January 09, 2026

    Mich. Bid For Behavioral Managed Care Contracts Can't Stand

    A Michigan Court of Claims judge ruled the state health department's bid for Medicaid managed care contract proposals would unlawfully interfere with the duties of local governmental bodies that provide and coordinate behavioral health care.

  • January 09, 2026

    Ex-Doximity Exec Cops To $2.5M Insider Trading Scheme

    The former chief revenue officer of publicly traded medical professional networking platform Doximity pled guilty Friday in New York federal court to securities fraud in connection to allegations that he illegally profited more than $2.5 million by trading on private information about the company's finances and layoff plans.

  • January 09, 2026

    9th Circ. Revives Suit Over Milliman's 'Fuzzy Matching' Tactic

    The Ninth Circuit on Friday reversed a decision tossing one of two classes in litigation accusing consulting firm Milliman of peddling inaccurate information by using a strategy known as "fuzzy" data matching to compile its reports, saying the lower court applied a too-high standard at the summary judgment stage for showing class members were harmed.

  • January 09, 2026

    Veterinary Group Says DOJ Accreditation Points Irrelevant

    The American Veterinary Medical Association has told a Tennessee federal court that the government's concerns about professional groups are irrelevant to a veterinary school's antitrust case challenging the association's accreditation requirements.

  • January 09, 2026

    Judge Denies 'Fatally Untimely' Bid For New Poaching Trial

    A Boston federal judge has denied what she called a "fatally untimely" motion for a new trial after a jury handed Cynosure LLC a $25 million verdict against two former employees who the company said caused other employees to breach their noncompete and nonsolicitation agreements.

  • January 09, 2026

    Judge Blocks Edwards' $945M Heart Valve Deal

    A D.C. federal judge issued an order on Friday preventing Edwards Lifesciences Corp. from moving ahead with its planned $945 million deal for JenaValve Technology Inc., torpedoing the merger challenged by the Federal Trade Commission.

  • January 09, 2026

    4 Argument Sessions That Benefits Attys Should Watch In Jan.

    The U.S. Supreme Court will zero in on the methodology for assessing liability for pulling out of a multi-employer pension fund, and the circuit courts will hear bids to revive suits over alleged 401(k) mismanagement and deferred compensation. Here, Law360 looks at a quartet of oral arguments coming up in January.

  • January 09, 2026

    Ex-Prosecutor OK For Drug Pricing MDL, Special Master Says

    Former Connecticut Assistant Attorney General Joseph Nielsen and his law firm, Lowey Dannenberg PC, should not be disqualified from representing insurers in multidistrict litigation over generic drug price-fixing because he did not have any special knowledge that the states suing drugmakers hadn't already shared with the private plaintiffs, according to a special master's report and recommendation.

  • January 09, 2026

    Biotech AirNexis Wraps Funding Round With $200M Raised

    Clinical stage biotech firm AirNexis, advised by Fenwick & West LLP, on Friday announced that it wrapped its Series A funding round with $200 million in tow, which will be used to fund the global clinical development of a therapy used for chronic obstructive pulmonary disease.

  • January 09, 2026

    Alaska Natives Challenge IHS Over Women's Health Services

    Two Alaskan corporations are asking a D.C. federal court to compel the U.S. Department of Health and Human Services to enter into a funding agreement that they say the Indian Health Service has rejected, arguing the denial threatens vital services to Alaska Natives and American Indians who have long depended on an Anchorage medical center.

Expert Analysis

  • How Healthcare Practices Can Prepare For ICE Visits

    Author Photo

    Healthcare providers that may face encounters with immigration enforcement should familiarize themselves with compliance obligations beyond ensuring employment authorization, and mitigate risk by establishing clear policies and specific procedures that safeguard patient rights and manage staff interactions with agents, say attorneys at Roetzel & Andress.

  • Adapting To Calif.'s Enhanced Regulation Of PE In Healthcare

    Author Photo

    New California legislation enhances oversight on the role of private equity groups and hedge funds in healthcare transactions, featuring both a highly targeted nature and vague language that will require organizations to carefully evaluate existing practices, says Andrew Demetriou at Husch Blackwell.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Federal Acquisition Rules Get Measured Makeover

    Author Photo

    The Trump administration's promised overhaul of the Federal Acquisition Regulation is not a revolution in rules, but a meaningful recalibration of procurement practice that gives contracting officers more space to think, to tailor and to try, say attorneys at Mayer Brown.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • AI Litigation Tools Can Enhance Case Assessment, Strategy

    Author Photo

    Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

  • Calif. Justices Continued Anti-Arbitration Trend This Term

    Author Photo

    In the 2024-2025 term, the California Supreme Court justices continued to narrow arbitration's reach under state law, despite state courts' extreme caseload backlog and even as they embraced contractual autonomy in other contexts, says Josephine Petrick at The Norton Law Firm.

  • Steps For Healthcare Providers After Cigna ERISA Settlement

    Author Photo

    Following the Cigna class action's settlement, where Employee Retirement Income Security Act violations arose from Cigna's online provider directory advertising providers as in-network who were actually out-of-network, providers should routinely audit their contract status and directory listings, and proactively coordinate with plans and payor partners, say attorneys at ArentFox Schiff.

  • DOJ's UnitedHealth Settlement Highlights New Remedies Tack

    Author Photo

    The use of divestitures and Hart-Scott-Rodino Act compliance in the recent U.S. Department of Justice settlement with UnitedHealth Group and Amedisys underscores the DOJ Antitrust Division's willingness to utilize merger remedies under the second Trump administration, say attorneys at Buchanan Ingersoll.

  • When Atty Ethics Violations Give Rise To Causes Of Action

    Author Photo

    Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.

  • What's New In FDA's Latest Cell And Gene Therapy Guidance

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.

  • H-1B Fee Guidance Is Helpful But Notable Uncertainty Persists

    Author Photo

    Recent guidance narrowing the scope of the $100,000 entry fee for H-1B visas will allow employers to plan for the hiring season, but a lack of detail about the mechanics of cross-agency payment verification, fee exemptions and other practical matters still need to be addressed, say attorneys at Klasko Immigration Law Partners.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.